Holista CollTech Limited operates as a biotech company in Australia, Malaysia, and the United States.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.058|
|52 Week High||AU$0.048|
|52 Week Low||AU$0.095|
|1 Month Change||-7.94%|
|3 Month Change||-1.70%|
|1 Year Change||-35.56%|
|3 Year Change||-17.14%|
|5 Year Change||-58.57%|
|Change since IPO||-55.39%|
Recent News & Updates
|HCT||AU Personal Products||AU Market|
Return vs Industry: HCT underperformed the Australian Personal Products industry which returned 22.4% over the past year.
Return vs Market: HCT underperformed the Australian Market which returned 24.4% over the past year.
Stable Share Price: HCT is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: HCT's weekly volatility (7%) has been stable over the past year.
About the Company
Holista CollTech Limited operates as a biotech company in Australia, Malaysia, and the United States. The company operates through Supplements, Ovine Collagen, Infection control Solutions, and Food Ingredients segments. It manufactures and wholesales dietary supplements; cosmetic grade collagen; and healthy food ingredients, including low-glycaemic index (GI) flour mix for noodles, pasta, flatbreads and other baked products, low-sodium salt, low-fat fried foods, less-calorie sugar, and low-GI sugar.
Holista CollTech Fundamentals Summary
|HCT fundamental statistics|
Is HCT overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|HCT income statement (TTM)|
|Cost of Revenue||AU$3.49m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.0045|
|Net Profit Margin||-15.14%|
How did HCT perform over the long term?See historical performance and comparison
Is Holista CollTech undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate HCT's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate HCT's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: HCT is unprofitable, so we can't compare its PE Ratio to the Global Personal Products industry average.
PE vs Market: HCT is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate HCT's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: HCT is overvalued based on its PB Ratio (3.6x) compared to the AU Personal Products industry average (2.4x).
How is Holista CollTech forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Household industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Holista CollTech has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Holista CollTech performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: HCT is currently unprofitable.
Growing Profit Margin: HCT is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: HCT is unprofitable, and losses have increased over the past 5 years at a rate of 33.3% per year.
Accelerating Growth: Unable to compare HCT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: HCT is unprofitable, making it difficult to compare its past year earnings growth to the Personal Products industry (23%).
Return on Equity
High ROE: HCT has a negative Return on Equity (-35.62%), as it is currently unprofitable.
How is Holista CollTech's financial position?
Financial Position Analysis
Short Term Liabilities: HCT's short term assets (A$5.2M) exceed its short term liabilities (A$2.1M).
Long Term Liabilities: HCT's short term assets (A$5.2M) exceed its long term liabilities (A$903.7K).
Debt to Equity History and Analysis
Debt Level: HCT's debt to equity ratio (17.6%) is considered satisfactory.
Reducing Debt: HCT's debt to equity ratio has reduced from 27.9% to 17.6% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: HCT has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: HCT has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of 39.7% each year.
What is Holista CollTech current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate HCT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate HCT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if HCT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if HCT's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of HCT's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Dr. Rajendran Manickavasagar A/L V. Marnickavasagar, also known as Rajen, B Ph.(Hons) has been the Chief Executive Officer of Holista CollTech Limited since July 10, 2009 and serves as its Managing Directo...
CEO Compensation Analysis
Compensation vs Market: Rajen's total compensation ($USD276.72K) is about average for companies of similar size in the Australian market ($USD301.38K).
Compensation vs Earnings: Rajen's compensation has increased whilst the company is unprofitable.
Experienced Management: HCT's management team is considered experienced (4.7 years average tenure).
Experienced Board: HCT's board of directors are not considered experienced ( 0.3 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Holista CollTech Limited's employee growth, exchange listings and data sources
- Name: Holista CollTech Limited
- Ticker: HCT
- Exchange: ASX
- Founded: NaN
- Industry: Personal Products
- Sector: Household
- Market Cap: AU$16.246m
- Shares outstanding: 275.35m
- Website: https://www.holistaco.com
- Holista CollTech Limited
- 283 Rokeby Road
- Western Australia
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/26 07:01|
|End of Day Share Price||2021/10/26 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.